Breaking 52 Week High, ProQR Therapeutics NV (Nasdaq:PRQR) Ends The Day At $18.65

PRQR
PRQR

ProQR Therapeutics NV (Nasdaq:PRQR)

September 10th, 2018

ProQR Therapeutics NV closed the day up $2.85 Tuesday, a 18.04% jump, closing at $18.65. Furthermore it hit a new 52 week high of $18.95. The stock continues to trade well at 578% of its 52 week low of $2.75. In addition to finishing higher, trading volumes were solid at 559% of normal which can indicate investors see opportunities. Be aware that the Piotroski Score1 is calculated to be 1, which is very low as the scale goes from 0-9. This is considered to be a weak score in terms of financial strength.

PRQR outperformed the rest of the Healthcare sector which went down 0.31% today.

Forecasts from 3 analysts suggest that ProQR Therapeutics NV could increase significantly (39%).

ProQR Therapeutics NV Info

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber’s congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington’s disease; and QRX-504 to treat Fuchs’ endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.

All amounts in USD unless otherwise indicated

(1) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (ProQR Therapeutics NV’s score is ), and 9 is the best.

PRQR daily update
PRQR daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.